The world’s second-largest drug maker, GlaxoSmithKline (GSK), is making India a major manufacturing hub for its free global drug supply to treat neglected diseases.

GSK would make additional investments in India and South Africa to increase production of anti-parasite drug albendazole to one billion tablets a year from 2012, Andrew Witty, chief executive officer of GSK, said in a tele-conference call from Japan.

Also Read   Related Stories News Now - Four top pharma firms bid for Paras - Taisho leads bids for India's Paras Pharma: report - Indian staple makes sense here, find drug MNCs - Five global drug cos approached for Paras stake: report - Panel may clear cervical cancer vaccine trials - Promoters have no intention to reduce stake: Dr Reddy's

Also Read   Related Stories News Now - Markets end on a strong note - Easing inflation a positive for China rating: Moody's - Falling oil price, gold import to help CAD in short-term: Kotak - Silver moves up on higher global cues - Shortage of petrol, diesel hits Chennai More

This would cost GSK an additional £12 million (Rs 84 crore) a year, said Witty. He said they needed regulatory approvals to supply albendazole from India, as their Indian production was only meant for use inside the country.

In March, Witty inaugurated a new albendazole manufacturing facility at Nashik in Maharashtra, at an investment of Rs 1.5 crore to supply 300 million treatments a year. The facility is part of a combination treatment used within the World Health Organization’s (WHO’s) global programme to eliminate lymphatic filariasis (LF).

Worldwide, more than 1.3 billion people live at risk of disability and disfigurement caused by LF, one-third of those at risk live in India. GSK supplies its entire production from the Nashik facility for the LF eradication programme in India.

Witty said GSK was developing a vaccine against malaria and the final phase of clinical trials were on in Africa.

Global drug makers supply select off-patent drugs as charity to various WHO programmes against neglected diseases. This includes Novartis’ donation of clofazimine treatment for leprosy and its complications, Sanofi-Aventis’ commitment against sleeping sickness elimination and Buruli ulcer, Chagas disease and leishmaniasis for the next five years, Bayer’s plans to give drugs for treating African sleeping sickness and Chagas disease, Eisai Pharma’s free drug supply of diethylcarbamazine to cure LF and Johnson & Johnson’s recent announcement to donate mebendazole for treating intestinal worms in children.

New Ipad Application :Business Standard's all new IPad App Click here to download for free Other Stories      - Markets end on a strong note - Easing inflation a positive for China rating: Moody's - Falling oil price, gold import to help CAD in short-term: Kotak - Silver moves up on higher global cues - Shortage of petrol, diesel hits Chennai

Tags : GlaxoSmithKline | anti-parasite drugs | free global drug supply | Andrew Witty | WHO |   Read Business news in  Advertisements -  Journey on, We are by Your Side. Click here to know more -  2 Lac Apartments, 1 Lac House / Plots. Click here -  Help a Child Achieve her. Click to know more -  Benefits Upto Rs. 2.36 Lakhs on the Fully Loaded TJet Petrol. -  The Best Seller is Also the No. 1 in Mileage. Click here -  Watch The Film Here. Click here to know more.. -  Leader in Passenger Car & Automobile Tyres. Click here -  1 billion in saving for Unilever without any tangles. -  A Brand New Server at a Price That Fits Your Budget. Click here -  Learn How One City is Running on FOOD SCRAPS. -  One Partnership Endless Possibilities. Click here to know more -  Helping doctors detect diseases earlier, saving costs & extending lives. -  36 Lakhs can get you a pool of Luxuries. Click here -  Which is the best plan for your daughter -  Check out the TRUE COLOURS of your Stocks, Now for FREE! -  One of the leading business schools in the world.Know More